Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a nasal spray shield aging brains from Post-Surgery confusion?

NCT ID NCT06945926

Prevention Sponsor: Zhejiang University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time

Summary

This trial tests whether oxytocin nasal spray can prevent postoperative delirium—a state of confusion that can occur after surgery—in older adults undergoing orthopedic procedures. Participants aged 65 and older will receive the spray before the end of anesthesia and twice daily for up to a week after surgery. The study will compare the rate of delirium in those receiving the spray against a control group to see if this simple intervention offers protection.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
oxytocin nasal spray
What this could lead to
If effective, this could offer a simple, non-drug way to prevent postoperative delirium in older surgical patients, potentially reducing complications and hospital stays.
What could go wrong
This is an early-phase trial, so the spray may not prove effective. Possible side effects or interactions are not yet fully known, and results may not apply to all surgical populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

227 people

The number who actually took part.

Started

Jun 2025

Finished

Jun 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Elderly patients undergoing orthopedic surgery under general anesthesia Inclusion criteria: 1. Age ≥ 65 years; 2. Patients who were to undergo elective orthopedic surgery under general anesthesia with tracheal intubation; 3. ASA class I-III; 4. Estimated duration of surgery ≥ 1 hour; (5) The patient himself/herself or his/her legal representative; 5. Informed consent from the patient or legal representative; 6. Proficiency in the use of Chinese language for communication. Exclusion criteria: 1. Nasal cavity occupation, patients with fillers in the nose 2. Oxytocin allergy; 3. Patients with previous psychiatric and neurological disorders, such as depression, severe central nervous system depression, Parkinson's disease, basal ganglia disease. Goldson's disease, basal ganglia lesions, schizophrenia, epilepsy, Alzheimer's disease, myasthenia gravis, and so on; 4. Pregnant and lactating women 5. Patients with severe hepatic insufficiency (Child-Pugh class C); 6. patients with severe renal insufficiency (dialysis is required before surgery) 7. Severe heart failure (METS\<4); 8. Preoperative inability to communicate (coma or dementia); 9. Severe preoperative blindness, deafness, or inability to understand Mandarin to complete preoperative delirium screening; 10. Preoperative cognitive impairment as determined by a MoCA evaluation prior to surgery; 11. Patients who are scheduled for 2 surgeries within 7 days of surgery; 12. Patients with bone malignancy 13. Currently participating in other clinical trials.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical spinal stenosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

avascular necrosis Emergence Delirium lumbar spinal stenosis Rotator Cuff Injuries rotator cuff syndrome spinal injury spinal stenosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical spinal stenosis Femoral head necrosis Knee joint injury Lumbar spinal stenosis Rotator cuff injury Spinal trauma Thoracic spinal stenosis

Contacts and locations

Locations

  • The First Affiliated Hospital, Zhejiang University School of Medicine

    Hangzhou, Zhejiang, 310000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.